Observational study of data, from large international collective of registers, finds similar overall drug retention rates between RA treatment groups.

The addition of JAKinibs to the armoury of RA therapy means clinicians, and patients with RA and an inadequate response/contraindication to csDMARDs, now have several second-line therapy options to choose from.

In the absence of head-to-head clinical trials, registry data provide a unique opportunity to compare available treatment options and understand the effectiveness of these therapies in clinical situations.

To this end, Lauper, et al. used data from 19 registers to evaluate and compare the real-world effectiveness of four different second-line therapies; TNFi, ABA, IL-6i and JAKinib.